Benign Prostatic Hyperplasia Pipeline Review H2 2011 Benign Prostatic Hyperplasia – Pipeline Review H2 2011

Document Sample
Benign Prostatic Hyperplasia Pipeline Review H2 2011 Benign Prostatic Hyperplasia – Pipeline Review H2 2011 Powered By Docstoc
					Benign Prostatic Hyperplasia – Pipeline Review, H2 2011




      Benign Prostatic Hyperplasia - Pipeline Review, H2
                            2011
                                                                                          Reference Code: GMDHC1339IDB

                                                                                          Publication Date: September 2011




Benign Prostatic Hyperplasia – Pipeline Review, H2 2011                                                       GMDHC1339IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                 Page(1)
Benign Prostatic Hyperplasia – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                                 2
List of Tables                                                                                                                    7
List of Figures                                                                                                                   9
Introduction                                                                                                                     10
     Global Markets Direct Report Coverage                                                                                       10
Benign Prostatic Hyperplasia Overview                                                                                            11
Therapeutics Development                                                                                                         12
     An Overview of Pipeline Products for Benign Prostatic Hyperplasia                                                           12
Benign Prostatic Hyperplasia Therapeutics under Development by Companies                                                         14
Benign Prostatic Hyperplasia Therapeutics under Investigation by Universities/Institutes                                         17
Late Stage Products                                                                                                              19
     Comparative Analysis                                                                                                        19
Mid Clinical Stage Products                                                                                                      20
     Comparative Analysis                                                                                                        20
Early Clinical Stage Products                                                                                                    21
     Comparative Analysis                                                                                                        21
Discovery and Pre-Clinical Stage Products                                                                                        22
     Comparative Analysis                                                                                                        22
Benign Prostatic Hyperplasia Therapeutics - Products under Development by Companies                                              23
Benign Prostatic Hyperplasia Therapeutics - Products under Investigation by Universities/Institutes                              26
Companies Involved in Benign Prostatic Hyperplasia Therapeutics Development                                                      27
     Allergan, Inc.                                                                                                              27
     QLT Inc.                                                                                                                    27
     Eli Lilly and Company                                                                                                       28
     Daiichi Sankyo Company, Ltd                                                                                                 28
     Euroscreen S.A.                                                                                                             29
     Light Sciences Oncology, Inc.                                                                                               29
     Aphios Corporation                                                                                                          30
     Astellas Pharma Inc.                                                                                                        30
     Dong-A Pharmaceutical Co., Ltd.                                                                                             31
     Kissei Pharmaceutical Co., Ltd.                                                                                             31
     Sun Pharmaceutical Industries Limited                                                                                       32
     Ascend Therapeutics, Inc.                                                                                                   32
     Bayer AG                                                                                                                    33
     Addex Pharmaceuticals                                                                                                       33
     AEterna Zentaris Inc.                                                                                                       34
     Nymox Pharmaceutical Corporation                                                                                            34
     Plethora Solutions Holdings plc                                                                                             35
     Protox Therapeutics Inc.                                                                                                    35
     Ajanta Pharma Limited                                                                                                       36
     AndroScience Corporation                                                                                                    36
     Vantia Therapeutics                                                                                                         37
     NovaLead Pharma Pvt. Ltd.                                                                                                   37
     World of Health Biotech Co.Ltd                                                                                              38
     Pherin Pharmaceuticals, Inc.                                                                                                38
     Ausio Pharmaceuticals, LLC                                                                                                  39
     Milkhaus Laboratory, Inc.                                                                                                   39


Benign Prostatic Hyperplasia – Pipeline Review, H2 2011                                               GMDHC1339IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                          Page(2)
Benign Prostatic Hyperplasia – Pipeline Review, H2 2011


Benign Prostatic Hyperplasia - Therapeutics Assessment                                                               40
     Assessment by Monotherapy Products                                                                              40
     Assessment by Combination Products                                                                              41
     Assessment by Route of Administration                                                                           42
     Assessment by Molecule Type                                                                                     44
Drug Profiles                                                                                                        46
     Ozarelix - Drug Profile                                                                                         46
          Product Description                                                                                        46
          Mechanism of Action                                                                                        46
          R&D Progress                                                                                               46
     Cetrotide - Drug Profile                                                                                        47
          Product Description                                                                                        47
          Mechanism of Action                                                                                        47
          R&D Progress                                                                                               47
     AEZS-115 - Drug Profile                                                                                         49
          Product Description                                                                                        49
          Mechanism of Action                                                                                        49
          R&D Progress                                                                                               49
     ADX68692 - Drug Profile                                                                                         50
          Product Description                                                                                        50
          Mechanism of Action                                                                                        50
          R&D Progress                                                                                               50
     Sperol - Drug Profile                                                                                           51
          Product Description                                                                                        51
          Mechanism of Action                                                                                        51
          R&D Progress                                                                                               51
     KMD-3213 - Drug Profile                                                                                         52
          Product Description                                                                                        52
          Mechanism of Action                                                                                        52
          R&D Progress                                                                                               52
     NX-1207 - Drug Profile                                                                                          53
          Product Description                                                                                        53
          Mechanism of Action                                                                                        53
          R&D Progress                                                                                               53
     ASC-JM - Drug Profile                                                                                           55
          Product Description                                                                                        55
          Mechanism of Action                                                                                        55
          R&D Progress                                                                                               55
     PSD506 - Drug Profile                                                                                           56
          Product Description                                                                                        56
          Mechanism of Action                                                                                        56
          R&D Progress                                                                                               56
     VA106483 - Drug Profile                                                                                         58
          Product Description                                                                                        58
          Mechanism of Action                                                                                        58
          R&D Progress                                                                                               58
     Aptocine - Drug Profile                                                                                         59
          Product Description                                                                                        59




Benign Prostatic Hyperplasia – Pipeline Review, H2 2011                                   GMDHC1339IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(3)
Benign Prostatic Hyperplasia – Pipeline Review, H2 2011


          Mechanism of Action                                                                                        59
          R&D Progress                                                                                               59
     ML-04A - Drug Profile                                                                                           61
          Product Description                                                                                        61
          Mechanism of Action                                                                                        61
          R&D Progress                                                                                               61
     VLDM01 - Drug Profile                                                                                           62
          Product Description                                                                                        62
          Mechanism of Action                                                                                        62
          R&D Progress                                                                                               62
     PRX302 - Drug Profile                                                                                           63
          Product Description                                                                                        63
          Mechanism of Action                                                                                        63
          R&D Progress                                                                                               63
     AUS-131 - Drug Profile                                                                                          65
          Product Description                                                                                        65
          Mechanism of Action                                                                                        65
          R&D Progress                                                                                               65
     Pomegranate Tablets - Drug Profile                                                                              67
          Product Description                                                                                        67
          Mechanism of Action                                                                                        67
          R&D Progress                                                                                               67
     ESN-364 - Drug Profile                                                                                          68
          Product Description                                                                                        68
          Mechanism of Action                                                                                        68
          R&D Progress                                                                                               68
     Botox - Drug Profile                                                                                            69
          Product Description                                                                                        69
          Mechanism of Action                                                                                        69
          R&D Progress                                                                                               69
     Lemuteporfin - Drug Profile                                                                                     71
          Product Description                                                                                        71
          Mechanism of Action                                                                                        71
          R&D Progress                                                                                               71
     Andrin - Drug Profile                                                                                           72
          Product Description                                                                                        72
          Mechanism of Action                                                                                        72
          R&D Progress                                                                                               72
     Tadalafil - Drug Profile                                                                                        73
          Product Description                                                                                        73
          Mechanism of Action                                                                                        73
          R&D Progress                                                                                               73
     Zydena - Drug Profile                                                                                           74
          Product Description                                                                                        74
          Mechanism of Action                                                                                        74
          R&D Progress                                                                                               74
     Lycopene - Drug Profile                                                                                         75
          Product Description                                                                                        75




Benign Prostatic Hyperplasia – Pipeline Review, H2 2011                                   GMDHC1339IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(4)
Benign Prostatic Hyperplasia – Pipeline Review, H2 2011


          Mechanism of Action                                                                                        75
          R&D Progress                                                                                               75
     Tamsulosin Hydrochloride + Solifenacin Succinate - Drug Profile                                                 76
          Product Description                                                                                        76
          Mechanism of Action                                                                                        76
          R&D Progress                                                                                               76
     Tadalafil + Finasteride - Drug Profile                                                                          77
          Product Description                                                                                        77
          Mechanism of Action                                                                                        77
          R&D Progress                                                                                               77
     Silodosin - Drug Profile                                                                                        78
          Product Description                                                                                        78
          Mechanism of Action                                                                                        78
          R&D Progress                                                                                               78
     Naftopidil - Drug Profile                                                                                       79
          Product Description                                                                                        79
          Mechanism of Action                                                                                        79
          R&D Progress                                                                                               79
     L-O-M MCS - Drug Profile                                                                                        80
          Product Description                                                                                        80
          Mechanism of Action                                                                                        80
          R&D Progress                                                                                               80
     Levitra - Drug Profile                                                                                          82
          Product Description                                                                                        82
          Mechanism of Action                                                                                        82
          R&D Progress                                                                                               82
     BoNT/A - Drug Profile                                                                                           84
          Product Description                                                                                        84
          Mechanism of Action                                                                                        84
          R&D Progress                                                                                               84
     PH45 - Drug Profile                                                                                             85
          Product Description                                                                                        85
          Mechanism of Action                                                                                        85
          R&D Progress                                                                                               85
     BOTOX-A - Drug Profile                                                                                          86
          Product Description                                                                                        86
          Mechanism of Action                                                                                        86
          R&D Progress                                                                                               86
     botulinum toxin type A - Drug Profile                                                                           87
          Product Description                                                                                        87
          Mechanism of Action                                                                                        87
          R&D Progress                                                                                               87
     TUC202 - Drug Profile                                                                                           88
          Product Description                                                                                        88
          Mechanism of Action                                                                                        88
          R&D Progress                                                                                               88
     Tadalafil - Drug Profile                                                                                        89
          Product Description                                                                                        89




Benign Prostatic Hyperplasia – Pipeline Review, H2 2011                                   GMDHC1339IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(5)
Benign Prostatic Hyperplasia – Pipeline Review, H2 2011


          Mechanism of Action                                                                                                         89
          R&D Progress                                                                                                                89
     Naftopidil - Drug Profile                                                                                                        90
          Product Description                                                                                                         90
          Mechanism of Action                                                                                                         90
          R&D Progress                                                                                                                90
     Tamsulosin + Meloxicam - Drug Profile                                                                                            91
          Product Description                                                                                                         91
          Mechanism of Action                                                                                                         91
          R&D Progress                                                                                                                91
     Botulinum toxin A - Drug Profile                                                                                                 92
          Product Description                                                                                                         92
          Mechanism of Action                                                                                                         92
          R&D Progress                                                                                                                92
     ASP4901 - Drug Profile                                                                                                           93
          Product Description                                                                                                         93
          Mechanism of Action                                                                                                         93
          R&D Progress                                                                                                                93
     LY500307 - Drug Profile                                                                                                          94
          Product Description                                                                                                         94
          Mechanism of Action                                                                                                         94
          R&D Progress                                                                                                                94
     KSO-0400 - Drug Profile                                                                                                          95
          Product Description                                                                                                         95
          Mechanism of Action                                                                                                         95
          R&D Progress                                                                                                                95
     ASP0306 - Drug Profile                                                                                                           96
          Product Description                                                                                                         96
          Mechanism of Action                                                                                                         96
          R&D Progress                                                                                                                96
Benign Prostatic Hyperplasia Ther
				
DOCUMENT INFO
Description: Benign Prostatic Hyperplasia - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2011', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia. - A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Benign Pro
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries